CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 

Syros Pharmaceuticals Inc 's Long Term Debt to Equity

SYRS's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In Spite of the long-term debt repayement of -3.72%, in III Quarter 2023 ,Long Term Debt to Equity deteriorated to 1.09 is above the company's typical Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 83 other companies have achieved lower Long Term Debt to Equity than Syros Pharmaceuticals Inc in the III Quarter 2023. While Long Term Debt to Equity total ranking has deteriorated compared to the second quarter 2023 from 1061 to 1744 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt SYRS´s has?
What is the structure of SYRS´s Equity?


SYRS Long Term Debt to Equity (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -71.9 % 136.11 % 70.15 % 49.89 % 21.79 %
Y / Y Long Term Debt Change -2.73 % 20.5 % 0.88 % 0.97 % 1.1 %
Long Term Debt to Equity MRQ 1.09 0.56 0.37 0.32 0.31
SYRS's Total Ranking # 1744 # 1061 # 1016 # 860 # 1027
Seq. Equity Change -50.43 % -31.39 % -16.43 % -1.11 % 316.43 %
Seq. Long Term Debt Change -3.72 % 4.63 % -3.77 % 0.33 % 19.27 %



Long Term Debt to Equity third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 84
Healthcare Sector # 231
Overall Market # 1744


Long Term Debt to Equity Statistics
High Average Low
1.1 0.31 0
(Jun 30 2022)   (Mar 31 2018)




Financial Statements
Syros Pharmaceuticals Inc 's Equity $ 36 Millions Visit SYRS's Balance sheet
Syros Pharmaceuticals Inc 's Long Term Debt $ 39 Millions Visit SYRS's Balance sheet
Source of SYRS's Sales Visit SYRS's Sales by Geography


Cumulative Syros Pharmaceuticals Inc 's Long Term Debt to Equity

SYRS's Long Term Debt to Equity for the trailling 12 Months

SYRS Long Term Debt to Equity

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -71.9 % 136.11 % 70.15 % 49.89 % 21.79 %
Y / Y Long Term Debt TTM Growth -2.73 % 20.5 % 0.88 % 0.97 % 1.1 %
Long Term Debt to Equity TTM 0.47 0.37 0.39 0.44 0.5
Total Ranking TTM # 1448 # 1303 # 1406 # 1697 # 1731
Seq. Equity TTM Growth -50.43 % -31.39 % -16.43 % -1.11 % 316.43 %
Seq. Long Term Debt TTM Growth -3.72 % 4.63 % -3.77 % 0.33 % 19.27 %


On the trailing twelve months basis Despite of the long-term debt repayement of -3.72% in the trailing twelve months ending in III Quarter 2023, Long Term Debt to Equity improved to 0.47, above Syros Pharmaceuticals Inc 's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 5, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Syros Pharmaceuticals Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 77 to 2191.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt SYRS´s has?
What is the structure of SYRS´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 15
Within the Market # 1744


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.54 0.22 0
(Jun 30 2022)   (Sep 30 2019)




Companies with similar Long Term Debt to Equity in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquitySep 30 2023 MRQ Long Term DebtSep 30 2023 MRQ Equity
Amicus Therapeutics inc   2.96 $ 394.071  Millions$ 133.237  Millions
Collegium Pharmaceutical Inc   2.95 $ 527.709  Millions$ 178.873  Millions
Teva Pharmaceutical Industries Limited  2.46 $ 18,495.000  Millions$ 7,512.000  Millions
Harrow Inc   2.42 $ 182.186  Millions$ 75.402  Millions
Puma Biotechnology Inc   1.98 $ 76.634  Millions$ 38.742  Millions
Ionis Pharmaceuticals Inc  1.78 $ 561.609  Millions$ 315.460  Millions
Milestone Pharmaceuticals inc   1.72 $ 48.915  Millions$ 28.504  Millions
Phibro Animal Health Corporation  1.68 $ 458.717  Millions$ 273.069  Millions
Sarepta Therapeutics Inc   1.62 $ 1,236.755  Millions$ 764.357  Millions
Eli Lilly And Company  1.59 $ 17,923.600  Millions$ 11,307.400  Millions
Jazz Pharmaceuticals Plc  1.46 $ 5,110.757  Millions$ 3,489.373  Millions
Travere Therapeutics Inc   1.35 $ 376.833  Millions$ 279.766  Millions
Alimera Sciences Inc   1.31 $ 64.222  Millions$ 48.840  Millions
Zoetis Inc   1.29 $ 6,552.000  Millions$ 5,074.000  Millions
Cerevel Therapeutics Holdings Inc   1.23 $ 336.933  Millions$ 272.962  Millions
Blueprint Medicines Corporation  1.20 $ 243.294  Millions$ 202.611  Millions
G1 Therapeutics Inc   1.19 $ 51.246  Millions$ 43.022  Millions
Marinus Pharmaceuticals Inc   1.19 $ 64.783  Millions$ 54.537  Millions
Mirum Pharmaceuticals Inc   1.14 $ 306.022  Millions$ 269.081  Millions
Catalent Inc   1.13 $ 4,322.000  Millions$ 3,841.000  Millions
Bristol myers Squibb Company  1.11 $ 32,137.000  Millions$ 29,062.000  Millions
Syros Pharmaceuticals Inc   1.09 $ 39.406  Millions$ 36.302  Millions
Amphastar Pharmaceuticals Inc   1.07 $ 638.206  Millions$ 595.140  Millions
Petros Pharmaceuticals inc   1.05 $ 7.249  Millions$ 6.933  Millions
Verrica Pharmaceuticals Inc   1.00 $ 42.401  Millions$ 42.303  Millions
Eterna Therapeutics Inc   0.97 $ 3.452  Millions$ 3.562  Millions
Elanco Animal Health Inc  0.96 $ 5,870.000  Millions$ 6,134.000  Millions
Pds Biotechnology Corp  0.96 $ 23.413  Millions$ 24.484  Millions
Perrigo Company Plc  0.85 $ 4,048.500  Millions$ 4,738.100  Millions
Merck and Co Inc   0.82 $ 33,972.000  Millions$ 41,300.000  Millions

Date modified: 2023-11-16T19:22:29+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com